Dominic Balog-Way
Dominic Balog-Way
Verified email at cornell.edu
TitleCited byYear
Transparency in Europe: a quantitative study
F Bouder, D Way, R Löfstedt, D Evensen
Risk Analysis 35 (7), 1210-1229, 2015
262015
Transparency and trust in the European pharmaceutical sector: outcomes from an experimental study
R Löfstedt, D Way
Journal of Risk Research 19 (9), 1082-1103, 2016
172016
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
D Way, F Bouder, R Löfstedt, D Evensen
Journal of Risk Research 19 (9), 1185-1215, 2016
92016
Pharmaceutical benefit–risk communication tools: a review of the literature
D Way, H Blazsin, R Löfstedt, F Bouder
Drug safety 40 (1), 15-36, 2017
62017
Transparency of medicines data and safety issues–a European/US study of doctors’ opinions: what does the evidence show?
R Löfstedt, D Way, F Bouder, D Evensen
Journal of Risk Research 19 (9), 1172-1184, 2016
42016
Transparency and trust in the European pharmaceutical sector: a Commentary
R Lofstedt, D Way
Journal of Risk Research 19 (9), 1120-1128, 2016
42016
Transparency in risk regulation: the case of the European Medicines Agency
DHP Way
King's College London, 2017
32017
How to Measure the Impact of Pharmacovigilance Activities on Public Health?
H Gardarsdottir, A Kant, ML De Bruin, CE Hallgren, G Dal Pan, D Way
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 31-31, 2017
2017
How risks are perceived. Recent research findings
D Way, F Bouder, R Löfstedt
Clinical Therapeutics 37 (8), e161-e162, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–9